Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relmada Therapeutics, Inc.

0.3230
+0.033211.46%
Post-market: 0.3170-0.0060-1.86%18:52 EDT
Volume:798.65K
Turnover:256.70K
Market Cap:10.72M
PE:-0.12
High:0.3405
Open:0.3001
Low:0.3001
Close:0.2898
Loading ...

Relmada Therapeutics To Present NDV-01 Data at AUA2025

GlobeNewswire
·
14 Apr

Q4 2024 Relmada Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
28 Mar

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ...

GuruFocus.com
·
28 Mar

Relmada Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

BRIEF-Relmada Therapeutics Q4 EPS USD -0.62

Reuters
·
28 Mar

Relmada Therapeutics Q4 EPS USD -0.62

THOMSON REUTERS
·
28 Mar

Relmada Therapeutics: Expect Topline Phase 2 Data for Ndv-01 for High-Grade Non-Muscle Invasive Bladder Cancer (Hg-Nmibc)

THOMSON REUTERS
·
28 Mar

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

GlobeNewswire
·
28 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

BRIEF-Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing

Reuters
·
27 Mar

Relmada Therapeutics Inc -on March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing

THOMSON REUTERS
·
27 Mar

BRIEF-Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Reuters
·
25 Mar

Relmada- to Pay up to $200 Mln in Development, Regulatory,Sales Milestones Pending Successful Commercialization

THOMSON REUTERS
·
25 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
22 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
20 Mar

Relmada Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview

Reuters
·
15 Mar

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

Asarina Pharma Ab (Publ) - Signs Asset Purchase Agreement With Relmada Therapeutics

THOMSON REUTERS
·
07 Feb

Relmada Therapeutics acquires Sepranolone from Asarina Pharma

TIPRANKS
·
06 Feb